GERON CORP

GERN Nasdaq CIK: 0000886744

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404
Mailing Address 919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA, 94404
Phone 6504737700
Fiscal Year End 1231
EIN 752287752

Financial Overview

FY2025

-$83.50M
Net Income
$593.78M
Total Assets
$-0.13
EPS

Recent SEC Filings

Form Type Date Filed Document
4 Insider stock transaction report April 1, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
4 Insider stock transaction report March 26, 2026 View on SEC
3 Initial insider ownership report March 26, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) March 3, 2026 View on SEC
10-K Annual financial report March 2, 2026 View on SEC
8-K Current report of material events February 25, 2026 View on SEC

Annual Reports

10-K March 2, 2026
  • Submitted New Drug Application (NDA) to the FDA for imetelstat in lower-risk MDS based on positive Phase 3 IMerge clinical trial data.
  • Ramped up commercialization efforts, building sales and marketing teams for a potential mid-2024 launch of imetelstat.
View Analysis

Material Events

8-K Layoffs December 16, 2025
High Impact
  • Geron Corp received FDA approval for Rytelo (imetelstat) in June 2024, marking a major milestone for its flagship product.
  • In December 2025, Geron announced a strategic restructuring plan, including a workforce reduction.
View Analysis

Insider Trading

SELL 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.